MedTrace Logo

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

NCT01860040 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-02-07

Study results available
· View outcomes & findings →

Summary

To determine the rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer (NSCLC)

Conditions

  • Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
  • Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

Cisplatin

Alkylating antineoplastic agent (Chemotherapy)

DRUG

Pemetrexed

Antimetabolite antineoplastic agent (Chemotherapy)

DRUG

Gemcitabine

Antimetabolite antineoplastic agent (Chemotherapy)

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • Glen Weiss, MD · Western Regional Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-09-30
Completion
2016-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01860040 on ClinicalTrials.gov